A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)

AstraZeneca

Status: Completed

Conditions: Healthy

Treatments: Drug: AZD8309

Study type: Interventional

Funder types: Industry

Identifiers

NCT00860821

D1511M00004

Details and patient eligibility

About

The purpose of this methodology study is to evaluate the effect of AZD8309 on cells and inflammatory biomarkers in nasal lavage and blood after nasal challenge with lipopolysaccharide (LPS)

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy men or healthy, permanently sterilized, women aged 18 to 50 years inclusive, non-smokers or ex-smokers, Body Mass Index 18 to 30 kg/m2 and minimum body weight of 50 kg
• Blood neutrophil count above 2.2x10^9/L

Exclusion criteria

• Clinical relevant disease and/or abnormality

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

20 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

AZD8309

Treatment:

Drug: AZD8309

Drug: AZD8309

2

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: AZD8309

Drug: AZD8309